Exchange: NASDAQ·Updated 06:37 PM EDT

IMRN News

News
all
press releases
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies (NASDAQ:BIAF) sharesread more...
Benzinga
More News
Digestive Health Expansion Sends This Microcap Soaring
Digestive health has become a sizable consumer-health category as patients increasingly look beyond short-term symptom relief toward products designed for regular use. In the U.S. alone, the digestive and gut health supplement market is estimated at $4.16 billion by one industry estimate, creating a broad commercial opportunity for companies that can carve out focused niches within the category.Shares of Immuron Limited (NASDAQ: IMRN) are surging Friday after the Australian biopharmaceutical company announced an exclusive U.S. distribution agreement with Sweden-based Calmino group AB for ...
AllPennyStocks.com
IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today?
Immuron signed an agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S
Stocktwits
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million. Akanda (NASDAQ:AKAN) shares increased by 27.52% to $4.68.read more...
Benzinga
Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up
(RTTNews) - Australian biopharmaceutical company Immuron Ltd. (IMC.AX, IMRN), announced on Friday that it has signed an exclusive distribution deal with Sweden's Calmino group AB to launch its digestive health product PROIBS in the United States, following its rollout in Australi...
Nasdaq News: Markets
Immuron Takes PROIBS to America, as New U.S. Growth Engine Could be Taking Shape
Immuron (NASDAQ:IMRN) is adding another potentially important piece to its U.S. commercial strategy, announcing an exclusive distribution agreement with Sweden’s Calmino group AB to bring PROIBS to the American market. The move expands Immuron’s digestive-health portfolio beyond Travelan and gives the company another commercial product aimed at a large and recurring consumer-health need: the symptoms associated with irritable bowel syndrome. Importantly, this is not a molecule sitting years away from commercialization. PROIBS has already been sold in Sweden for more than a decade and, according to Calmino, was the best-selling IBS product in Swedish pharmacies during 2025, based on IQVIA sales data.
24-7 Market News
Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates
CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs.
Stocktwits

Advertisement|Remove ads.